.

.

• Rafael Alonso, Institute of Biomedical Technologies, CIBICAN, ULL (Tenerife. Spain)
• Why Tenerife,   a   project   aimed   at   promoting   the   economic,   social,   and   cultural development of Tenerife through the creation of a solid business and commercial base on the island (http://www.whytenerife.com/quienes-­‐somos/). 

   
   

• Measuring (not estimating) renal function in special clinical conditions – Esteban Porrini, Institute of Biomedical Technologies, CIBICAN, ULL (Tenerife, Spain)
• Inducer of autophagy by D3R in neurons and lymphocyte – Tomás González, Institute of Biomedical Technologies, CIBICAN, ULL (Tenerife, Spain)
• Development of novel molecular therapies for Primary Hyperoxalury I – Miguel Fernandes, Institute of Biomedical Technologies, CIBICAN, ULL (Tenerife, Spain)
• Alternative and innovative therapeutic strategies for Pompe disease – Eduardo Salido, University Hospital of Canary Islands, Institute of Biomedical Technologies, CIBICAN, ULL (Tenerife, Spain)

.

A model and possible road-map for the development of a successful new biomedical & biotechnology institute outside of the usual hot-spots

Moderator: Manuel López-­‐Figueroa 

• Richard Myers, President,  Director  &  Faculty  Investigator,  HudsonAlpha  Institute  for Biotechnology, Huntsville (Alabama, USA) 

.

Case studies in successful approaches & models

Moderator: Christian J. Suojanen 

• Mike Johnson, Director Corporate Partnership, MRC Technology (London, UK) 
• Miriam Zeini, Manager, Science and Technology Transfer, Fundación Botín (Madrid, Spain)
• Susanne Letzelter, Corporate Development & Communication, Ascenion GmbH (Munich, Germany)

From innovative ideas to startups

Moderator: Manuel López-­‐Figueroa 

• Robert Kay, Managing Partner, Parallax Biotechnology Advisors (San Francisco, CA, USA) 
• Anne Leschin, Co-Founder & Principal, StreetSmart Investor Relations (San Francisco, CA, USA) 
• Sara Marsal, Head Reumathology Research Group, ResearVall d’Hebron University Hospital (Barcelona, Spain) 
• Javier García-Cogorro, Managing Partner, Synthesis Capital (Madrid, Spain) 

.

Partnering and licensing

Moderator: Manuel López-­‐Figueroa 

• Robert Elfont, Strategic Clinical Development, LLC (San Francisco, CA, USA)
• Oliver Chao,  Head, Strategy and External Innovation, Sanofi (Paris, France)
• Jesús Hernández, CEO, Center for Applied Medical Research, University of Navarra (Pamplona, Spain)
• Sanford S. Zweifach, CEO & Founder, Ascendancy Healthcare (San Francisco, CA, USA)

• Manuel Lopez-Figueroa, Vicepresident, Bay City Capital (San Francisco, CA, USA)
• Laia Crespo, Investment Director, Ysios Capital (Barcelona, Spain)
• Graeme Martin, CEO, Takeda Ventures Inc. (Palo Alto, CA, USA)
• Jose A. Mesa, Investment Director, Caixa Capital Risk VC (Barcelona, Spain)

.

.